Cowen and Company’s Clovis Oncology, Inc. CLVS Stock Holding History

Cowen and Company’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-528,600	Closed	-$444K	–	787
2021 Q2	$444K	Buy	+528,600	New	+$3.1M	0.02%	193
2020 Q2	–	Sell	-180,000	Closed	-$18K	–	498
2020 Q1	$18K	Buy	+180,000	New	+$1.44M	﹤0.01%	331
2019 Q4	–	Sell	-95,000	Closed	-$33K	–	637
2019 Q3	$33K	Buy	+95,000	New	+$768K	0.01%	350

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cowen and Company's CLVS Position: Q4 2021 in Review

Cowen and Company sold out of Clovis Oncology, Inc. (CLVS) in Q4 2021, closing a stake of 41,492 shares — an estimated $185K sold.

Cowen and Company first reported a position in CLVS in Q1 2020 and held it in 2 quarters. The position peaked at $2.96M in Q1 2020. 153 funds tracked by Wall St. Rank hold CLVS as of Q4 2021.

Cowen and Company reported no remaining Clovis Oncology, Inc. position as of Q4 2021 after selling out during the quarter.
Cowen and Company sold 41,492 Clovis Oncology, Inc. shares in Q4 2021, an estimated $185K.
Cowen and Company first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 2 quarters.
Cowen and Company's Clovis Oncology, Inc. position peaked at $2.96M in Q1 2020.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.